Apoptosis in liver disease

Journal of Hepatology

Volumn 27, Issue 2, 1997, Pages 405-412

  Galle, Peter R ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; FAS ANTIGEN; LIGAND; ONCOPROTEIN; PROTEIN BCL 2; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE; PROTEIN P53; PROTEINASE; RECEPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1; TUMOR NECROSIS FACTOR;

APOPTOSIS; CYTOTOXIC T LYMPHOCYTE; DNA DEGRADATION; HEPATITIS B VIRUS; LIVER CARCINOGENESIS; LIVER CARCINOMA; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 0030858904     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-8278(97)80189-4     Document Type: Review

References (87)

1. Kerr JFR. Shrinkage necrosis: a distinct mode of cellular death. J Pathol. 105:1971;13-20.
2. Kerr JFR, Whyllie AH, Curries AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 26:1972;239-257.
3. Steller H. Mechanisms and genes of cellular suicide. Science. 267:1995;1445-1449.
4. Schulte-Hermann R, Timmermann-Trosiener I, Barthel G, Bursch W. DNA synthesis, apoptosis, and phenotypic expression as determinants of growth of altered foci in rat liver during phenobarbital promotion. Cancer Res. 50:1990;5127-5135.
5. Schulte-Hermann R, Grasl-Kraupp B, Bursch W. Apoptosis and hepatocarcinogenesis. Jirtle RL. Liver Regeneration and Carcinogenesis. 1995;Academic Press, New York.
6. Alison MR, Saraf CE. Liver cell death: patterns and mechanisms. Gut. 35:1994;577-581.
7. Collins RJ, Harmon BK, Gobe GC, Kerr JF. Internucleosomal DNA cleavage should not be the sole criterion for identificatifying apoptosis. Int J Radiat Biol. 61:1992;451-453.
8. Whyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 284:1980;555-556.
9. Rosser B, Gores G. Liver cell necrosis: cellular mechanisms and clinical implications. Gastroenterology. 108:1995;252-275.
10. Patel T, Gores GJ. Apoptosis and hepatobiliary disease. Hepatology. 21:1995;1725-1741.
11. Cotter TG, Al-Rubeai M. Cell death (apoptosis) in cell culture systems. TIBTECH. 13:1995;150-155.
12. Oberhammer FA, Wilson JW, Dive C, Morris ID, Hickman JA, Wakeling AE, et al. Apoptotic death in epithelial cells: cleavage of DNA to 3000 and/or 59 kb fragments prior to or in the absence of internucleosomal fragmentation. EMBO J. 12:1993;3679-3684.
13. Hughes FM Jr., Cidlowsk JA. Apoptotic DNA degradation: evidence for novel enzymes. Cell Death Different. 1:1994;11-17.
14. Walker PR, Weaver VM, Lach B, LeBlanc J, Sikorsa M. Endonuclease activities associated with high molecular weight and internucleosomal DNA fragmentation in apoptosis. Exp Cell Res. 351:1994;150-154.
15. Arends MJ, Morris RG, Wyllie AH. Apoptosis. The role of the endonuclease. Am J Pathol. 136:1990;593-607.
16. Schulze-Osthoff K, Walczak H, Dröge W, Krammer PH. Cell nucleus and DNA fragmentation are not required for apoptosis. J Cell Biol. 127:1994;15-20.
17. Grasl-Kraupp B, Ruttkay Nedecky B, Koudelka H, Bukowska K, Bursch W, Schulte Hermann R. In situ detection of fragmented DNA (TUNEL assay) fails to discriminate among apoptosis, necrosis, and autolytic cell death: a cautionary note. Hepatology. 21:1995;1465-1468.
18. Nicoletti I, Migliorati G, Paggliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide and flow cytometry. J Immunol Meth. 139:1999;271-279.
19. Li X, James WM, Traganos F, Darzynkiewicz Z. Application of biotin, digoxigenin or fluorescein conjugated deoxynucleotides to label DNA strand breaks for analysis of cell proliferation and apoptosis using flow cytometry. Biotech Histochem. 70:1995;234-242.
20. Li X, Melamed R, Darzynkiewicz Z. Detection of apoptosis and DNA replication by differential labeling of DNA strand breaks with fluorochromes of different color. Exp Cell Res. 222:1996;28-37.
21. Fesus L, Thomazy V, Falus A. Induction and activation of tissue transglutaminase during programmed cell death. FEBS Lett. 224:1987;104-108.
22. Tarcsa E, Kadei N, Thomazy V, Fesus L. An involucrin-like protein in hepatocytes serves as a substrate for tissue transglutaminase during apoptosis. J Biol Chem. 267:1992;15648-15651.
23. Piacentini M, Davies P, Fesus L. Tissue transglutaminase in cells undergoing apoptosis. Tomei LD, Cope F. Apoptosis II: the molecular basis of apoptosis in disease. 1994;143-163 Cold Spring Harbor Press, New York.
24. Kojima S, Nara K, Rifkin DB. Requirement for transglutaminase in the activation of latent transforming growth factor-β in bovine endothelial cells. J Cell Biol. 121:1993;439-448.
25. Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today. 14:1993;131-136.
26. Dini L, Autuori F, Lentini A, Oliviero S, Piacentini M. The clearance of apoptotic cells in the liver is mediated by the asialoglycoprotein receptor. FEBS Lett. 296:1992;174-178.
27. Dini L, Falasca L, Lentini A, Mattioli P, Piacentini M, Pireda, et al. Galactose-specific receptor modulation related to the onset of apoptosis in rat liver. Eur J Cell Biol. 61:1993;329-337.
28. Patel T, Gores GJ, Kaufmann SH. The role of proteases during apoptosis. FASEB J. 10:1996;587-597.
29. Miura M, Zhu H, Rotello R, Hartwieg E, Yuan J. Induction of apoptosis in fibroblasts by Il-1 beta-converting enzyme, a mammalian homolog of the C. elegans cell death gene ced-3. Cell. 75:1993;653-660.
30. Henkart PA. ICE family proteases: mediators of all apoptotic cell death? Immunity. 4:1996;195-201.
31. Nicholson DW, Ali A, Thornberry NA, Vaillancourt JP, Ding CK, Gallant M, et al. Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature. 376:1995;37-43.
32. Nagata S, Golstein P. The Fas death factor. Science. 267:1995;1449-1456.
33. Thompson CB. Apoptosis in the pathogenesis and treatment of disease. Science. 267:1995;1456-1462.
34. Galle PR, Hofmann WJ, Walczak H, Schaller H, Otto G, Stremmel N, et al. Involvement of the APO-1/Fas (CD95) receptor and ligand in liver damage. J Exp Med. 182:1995;1223-1230.
35. Ogasawara J, Watanabe Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 364:1993;806-809.
36. Owen-Schaub LB, Radinsky R, Kruzel E, Berry K, Yonehara S. Anti-Fas on nonhematopoietic tumors: levels of Fas/APO-1 and bcl-2 are not predictive of biological responsiveness. Cancer Res. 54:1994;1580-1586.
37. Suda T, Takahashi T, Goldstein P, Nagata S. Molecular cloning and expression of the Fas ligand, a member of the tumor necrosis factor family. Cell. 75:1993;1169-1178.
38. Mariani SM, Matiba B, Bäumler C, Krammer PH. Regulation of cell surface APO-1/Fas (CD95) ligand expression by metalloproteases. Eur J Immunol. 25:1995;2303-2307.
39. Tracey KJ, Cerami A. Tumor necrosis factor, other cytokines and diseases. Annu Rev Cell Biol. 9:1993;317-343.
40. Vandenabeele P, Declercg W, Beyaert R, Fiers W. Two tumour necrosis factor receptors: structure and function. Trends Cell Biol. 5:1995;392-399.
41. Tartaglia LA, Goeddel DV. Two TNF receptors. Immunol Today. 13:1992;151-153.
42. Smith CA, Farrah T, Goodwin RG. The TNF receptor super-family of cellular and viral proteins: activation, costimulation and death. Cell. 76:1994;959-962.
43. Liu Z, Hsu H, Goeddel DV, Karin M. Dissection of TNF receptor 1 effector functions: JNK activation is not linked to apoptosis while NF-kB activation prevents cell death. Cell. 87:1996;565-576.
44. Wiley SR, Schooley K, Smolak PJ, Din WS, Huang CP, Nicholl JK, et al. Indentification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 3:1997;673-682.
45. Pitti RM, Marsters SA, Rupper S, Donahue CJ, Moore A, Ashkenazi A. Induction of apoptosis by APO-2 ligand, a new member of the TNF cytokine family. J Biol Chem. 271:1996;12687-12690.
46. Marsters SA, Pitti RM, Donahue CJ, Rupper S, Bauer KD, Ashkenazi A. Activation of apoptosis by APO-2 ligand is independent of FADD but blocked by crmA. Curr Biol. 6:1996;750-752.
47. Fan G, Ma X, Kren BT, Steer CJ. The retinoblastoma gene product inhibits TGF-betal induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells. Oncogene. 12:1996;1909-1919.
48. Oberhammer FA, Pavelka M, Sharma S, Tiefenbacher R, Purchio A, Bursch W, et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor β1. Proc Natl Acad Sci USA. 89:1992;5408-5412.
49. Oberhammer FA, Bursch W, Tiefenbacher R, Frosch G, Pavelka M, Purchio T, et al. Apoptosis is induced by transforming growth factor-beta 1 within 5 hours in regressing liver without significant fragmentation of the DNA. Hepatology. 18:1993;1238-1246.
50. Oberhammer FA, Nagy P, Tiefenbacher R, Froschl G, Bouzahzah B, Thorgeirsson SS, et al. The antiandrogen cyproterone acetate induces synthesis of transforming growth factor beta 1 in the parenchymal cells of the liver accompanied by an enhanced sensitivity to undergo apoptosis and necrosis without inflammation. Hepatology. 23:1996;329-337.
51. Oberhammer FA, Qin HM. Effect of three tumour promoters on the stability of hepatocyte cultures and apoptosis after transforming growth factor-beta 1. Carcinogenesis. 16:1995;1363-1371.
52. Fukuda K, Kojiro M, Chiu JF. Induction of apoptosis by transforming growth factor-beta 1 in the rat hepatoma cell line McA-RH7777: a possible association with tissue transglutaminase expression. Hepatology. 18:1993;945-953.
53. Sanderson N, Factor V, Nagy P, Kopp J, Konaiah P, Wakefield L, et al. Hepatic expression of mature transforming growth factor beta 1 in transgenic mice results in multiple tissue lesions. Proc Natl Acad Sci USA. 92:1995;2572-2576.
54. Harris CC. p53 tumor suppressor gene: from the basic research laboratory to the clinic - an abridged historical perspective. Carcinogenesis. 17:1996;1187-1198.
55. Harris CC. Structure and function of the p53 tumor suppressor gene: clues for rational cancer therapeutic strategies. J Natl Cancer Inst. 88:1996;1442-1455.
56. Volkmann M, Hofmann WJ, Müller M, Räth U, Otto G, Zentgraf H, et al. p53 overexpression is frequent in European hepatocellular carcinoma and largely independent of the codon 249 hot spot mutation. Oncogene. 9:1994;195-204.
57. Bates S, Vousden KH. p53 in signaling checkpoint arrest or apoptosis. Curr Opin Genet Dev. 6:1996;12-19.
58. Lane DP. Cancer. p53, guardian of the genome. Nature. 358:1992;15-16.
59. Kastan MB, Onyekwere O, Sidransky D, Vogelstein B, Craig RW. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 51:1991;6304-6311.
60. Kuerbitz SJ, Plunkett BS, Walsh WV, Kastan MB. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc Natl Acad Sci USA. 89:1992;7491-7495.
61. Kastan MB, Zhan Q, El-Deiry WS, Carrier F, Jacks T, Walsh WV, et al. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-teleangiectasia. Cell. 71:1992;587-597.
62. Clarke AR, Purdie CA, Harrison DJ, et al. Thymocyte apoptosis induced by p53-dependent and independent pathway. Nature. 362:1993;849-852.
63. Lotem J, Sachs L. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood. 82:1993;1092-1096.
64. Lowe SW, Schmitt EM, Smith SW, Osborne BA, Jacks T. p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature. 362:1993;847-849.
65. Liebermann DA, Hoffman B, Steinman RA. Molecular controls of growth arrest and apoptosis: p53-dependent and independent pathways. Oncogene. 11:1995;199-210.
66. Lee ML, Bernstein A. Apoptosis, cancer and the p53 tumour suppressor gene. Cancer Metastasis Rev. 14:1995;149-161.
67. Müller M, Strand S, Hug H, Heinemann E-M, Walczak H, Hofmann WJ, et al. Drug-induced apoptosis in hepatoma cells involves activation of p53 is mediated by the CD95 (APO-1/Fas) receptor/ligand system. J Clin Invest. 99:1997;403-413.
68. Chiarugi V, Ruggiero M. Role of three cancer master genes p53, bcl2 and c-myc on the apoptotic progress. Tumorigenesis. 82:1996;205-209.
69. Reed JC. Regulation of apoptosis by bcl-2 family proteins and its role in cancer chemoresistance. Curr Opin Oncol. 7:1995;541-546.
70. Tsujimoto Y, Croce CM. Analysis of the structure, transcripts, and protein products of bcl-2, the gene involved in human follicular lymphoma. Proc Natl Acad Sci USA. 83:1986;5214-5218.
71. Que FG, Gores GJ. Cell death by apoptosis: basic concepts and disease relevance for the gastroenterologist. Gastroenterology. 110:1996;1238-1243.
72. Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 145:1994;1323-1336.
73. Bursch W, Taper HS, Lauer B, Schulte-Hermann R. Quantitative histological and histochemical studies on the occurrence and stages of controlled cell death (apoptosis) during regression of rat liver hyperplasia. Virchows Arch Cell Pathol. 50:1985;153-213.
74. Benedetti AA, Jezaquel M, Orlandi F. Preferential distribution of apoptotic bodies in acinar zone 3 of normal human and rat liver. J Hepatol. 7:1988;319-324.
75. Arber N, Zajicek G, Ariel I. The streaming liver II. Hepatocyte life history. Liver. 7:1988;319-324.
76. Oberhammer FA, Fristch G, Pavelka M, Froschl G, Tiefenbacher R, Purchio T, et al. Induction of apoptosis in cultured hepatocytes and in the regressing liver by transforming growth factor-beta 1 occurs without activation of an endonuclease. Toxicol Lett. 1992;701-704. 64-65 Spec No.
77. Grasl-Kraupp B, Bursch W, Ruttkay-Nedecky B, Wagner A, Lauer B, Schulte-Hermann R. Food restriction eliminates preneoplastic cells through apoptosis and antagonizes carcinogeneis in rat liver. Proc Natl Acad Sci USA. 91:1994;9995-9999.
78. Kaplowitz N. Recent advances in drug metabolism and hepatotoxicity. Semin Liver Dis. 10:1990;235-238.
79. Tsukidate K, Yamamoto K, Snyder J, Farber J. Microtubule antagonist activate programmed cell death (apoptosis) in cultured rat hepatocytes. Am J Pathol. 143:1993;918-925.
80. Patel T, Bronk S, Gores GJ. Increases of intracellular magnesium promote glycodeoxycholate-induced apoptosis in rat hepatocytes. J Clin Invest. 94:1994;2183-2192.
81. Bursch W, Oberhammer F, Schulte-Hermann R. Cell death by apoptosis and its protective role against disease. TIPS. 13:1992;245-251.
82. Roberts JM, Searle JW, Cooksley WG. Histological patterns of prolonged hepatitis C infection. Gastroenterology. 26:1993;37-41.
83. Ando K, Moriyama T, Guidotto L, Wirth S, Schreiber RD, Schlicht HJ, et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med. 178:1993;1541-1554.
84. Reed JC. Bcl-2 and the regulation of programmed cell death. J Cell Biol. 124:1994;1-6.
85. Krams SM, Egawa H, Quinn MB, Martinez OM. Apoptosis as a mechanism of cell death in liver allograft rejection. Transplantation. 59:1995;621-625.
86. Bursch W, Grasl-Kraupp B, Ellinger A, Torok L, Kienzl H, Mullauer L, et al. Active cell death: role in hepatocarcinogenesis and subtypes. Biochem Cell Biol. 72:1994;669-675.
87. Strand S, Hofmann WJ, Hug H, Müller M, Otto G, Strand D, et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand expressing tumor cells - a mechanism of immune evasion? Nature Med. 2:1996;1361-1367.